Publication date: Jul 04, 2025
High-dose IL-2 is required at the moment for TILs; [to tolerate that therapy] patients have to have excellent performance status, excellent cardiac function, lung function. For some patients, there could be some bridging optionsperhaps BRAF/MEK inhibitor therapy, as an example. However, that’s the biggest challenge right now. [For this therapy to be effective, the tumor must] have the PRAME antigen and the right HLA type, which is only about 40% of patients. Unfortunately, we’re still seeing 10% to 30% response rates in the frontline setting. Many patients don’t have the time to wait around for therapy. That is probably the biggest issue at this moment, because in general, it’s going to take several weeks for insurance approval to get done. Patients have to have 2 to 3 months for insurance approval, surgery scheduling, and product manufacturing, which takes about 5 weeks.
| Concepts | Keywords |
|---|---|
| Biomarkers | Agent |
| Chemotherapy | Cellular |
| Exciting | Frontline |
| Ima203 | High |
| Nashville | Il |
| Immunotherapy | |
| Johnson | |
| Melanoma | |
| Rates | |
| Setting | |
| Therapies | |
| Therapy | |
| Tils | |
| Treatment | |
| Tumor |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | relapse |
| drug | DRUGBANK | Pembrolizumab |
| disease | MESH | uveal melanoma |
| drug | DRUGBANK | Sarilumab |
| drug | DRUGBANK | Nivolumab |
| drug | DRUGBANK | Ipilimumab |
| disease | MESH | metastases |
| drug | DRUGBANK | Nonoxynol-9 |
| disease | MESH | tumor |
| pathway | KEGG | Melanoma |
| disease | MESH | Melanoma |
| drug | DRUGBANK | Tropicamide |